Strona główna・Stock List・Novocure Ltd

Novocure Ltd

Open

SectorHealthcare

14.78 -2.7

Buy Sell

Overview

Share price change

24h

Current

Min

15.02

Max

15.56

Key metrics
By Trading Economics
Income	55M -16M
Sales	9.5M 184M
EPS	-0.13
Profit margin	-8.529
Employees	1,605
EBITDA	53M -11M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+69.6% upside

Dividends
By Acuity
Next Earnings	29 paź 2026

Market Stats
By TradingEconomics
Market Cap	126M 2B
Previous open	17.48
Previous close	14.78

News Sentiment

By Acuity

55%

45%

276 / 340 Ranking in Healthcare

Novocure Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 lip 2026, 19:39 UTC

Novocure Ltd shares are higher today, recovering from an early dip. The stock remains below its 20-day moving average amid a trend of lower closes.

29 lip 2026, 18:55 UTC

Novocure Ltd's shares are declining today, reversing from a recent trend of higher daily closes. Earlier in the session, the stock briefly rebounded.

28 lip 2026, 23:31 UTC

Novocure Ltd. shares are lower in after-market hours, continuing a decline over the past four sessions and trading below the 20-day moving average.

27 lip 2026, 19:06 UTC

Novocure Ltd. shares are lower today amid a broader market decline influenced by a significant drop in crude oil prices.

24 lip 2026, 19:41 UTC

News

Social Media

Novocure Ltd's stock is lower following its Q2 earnings report, despite a narrower loss and revenue beat. Analysts lowered price targets amid ongoing investor concerns.

22 lip 2026, 20:04 UTC

Shares of Novocure Ltd. are lower today, continuing a decline since Tuesday's close amid broader market uncertainty ahead of the Federal Reserve meeting.

20 lip 2026, 14:36 UTC

Novocure Ltd. is trading higher since Friday's close, despite pulling back from an early session high amid broader market volatility from geopolitical tensions.

Peer Comparison

Price change

Novocure Ltd Forecast

Price Target

By TipRanks

69.6% upside

12 Months Forecast

Average 25.83 USD 69.6%

High 52 USD

Low 17 USD

Based on 6 Wall Street analysts offering 12 month price targets forNovocure Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Novocure Ltd - Dist in the past 3 months.

Sentiment

By Acuity

276 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.